HIGHLIGHTS
- who: Knut Ju00f8rgen Labori from the Department of Hepato-Pancreato-Biliary Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Institute of Moffitt Center, United States have published the paper: Short-Course or Total Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer - Current Status and Future Perspectives, in the Journal: (JOURNAL)
- what: By this approach, patients may rapidly achieve clinical benefits while more tailored treatments can be developed for each patient.
- future: The chemotherapeutic switch could be incorporated into neoadjuvant treatment sequencing in future trials.
SUMMARY
A major criticism of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.